In a report released yesterday, Allen Lutz from Bank of America Securities maintained a Buy rating on Envista Holdings, with a price target of $34.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Allen Lutz has given his Buy rating due to a combination of factors, including sustained business momentum and a resilient end market. Management indicates that dental demand remains steady into the second quarter, the company is gaining market share, and margins are improving as Envista continues to invest in innovation and its product pipeline, giving confidence in its ability to meet or exceed guidance if market conditions hold.
In addition, multiple growth engines support the outlook toward 2026 and beyond, such as above-market growth in infection-prevention consumables, accelerating adoption of Spark aligners in Europe and new markets like Japan, and a shift in diagnostics from recovery to a true growth contributor through installed-base leverage and software monetization. While management acknowledges macro, cost, and China-related policy risks, it believes existing strategies and targeted M&A, combined with geographic expansion and pricing power, position Envista to deliver superior growth, justifying a maintained $34 price target and Buy recommendation.
In another report released on May 7, Stifel Nicolaus also maintained a Buy rating on the stock with a $31.00 price target.
NVST’s price has also changed moderately for the past six months – from $19.400 to $23.860, which is a 22.99% increase.